Private Equity Partners and Venture Capital Platform Teams
Your Value Creation Plan Is Written. Your Portfolio Company Is Executing It. So Why Is the EBITDA Still Not Moving?
You have seen this before. A portfolio company with a capable management team, a reasonable market position, and a value creation plan that was built on solid analysis. The operating partner is engaged. The quarterly reviews are happening. The initiatives are being tracked. And twelve months into the hold period the EBITDA improvement that was supposed to be well underway is instead a series of explanations about why the initiatives are taking longer than projected.
You sit in the board meeting knowing something is structurally wrong. The management team is not the problem. The market has not materially changed. The initiatives are being executed with reasonable discipline. And the needle is still not moving at the rate the investment thesis requires. You can feel the constraint. You cannot name it precisely enough to change the conversation — which means the next board meeting will produce the same conversation as this one.
That feeling is the diagnostic gap. The constraint that is limiting your portfolio company's performance right now was present when the deal closed. It was present when the value creation plan was written. It is still present now — governing every result the company produces while every improvement initiative works around it rather than through it. The $89 Business Constraint Diagnostic closes that gap in writing within 72 hours. Deployed before the value creation plan is written, it costs less than one minute of operating partner advisory fees and changes every conversation that follows.
Present at close. Still governing the performance today.
"The thesis was right. The team was strong. The market was real. And the portfolio company is underperforming for the fourth consecutive quarter with a different explanation each time. The governing constraint underneath every explanation has not changed — and has never been named. It was in the business at close. It is still there now."
The 12 Realities Every PE Operating Partner Recognizes
If that board meeting sounds familiar, the following twelve realities will be recognizable.
- The value creation plan identified the right initiatives. The EBITDA improvement is not materializing on schedule because the governing constraint that limits all of those initiatives simultaneously was never identified before the plan was written.
- The management team is executing. The operating partner is engaged. The board is aligned. And the results are still not moving at the pace the investment thesis requires — which means the problem is structural, not motivational.
- Due diligence identified the financial constraints visible in the statements. The operational constraint governing those financial results was not visible in the statements — and was not identified before the deal closed.
- A portco management team is resisting the value creation recommendations not because they are wrong but because the team cannot see the connection between the recommendation and the actual constraint governing their results.
- The hold period is extending. The LP narrative is shifting from value creation timeline to market conditions. The governing constraint is still in place and is now compounding the pressure from every direction simultaneously.
- A roll-up acquisition was integrated before the governing constraint in the platform company was identified. The acquired company is now replicating the platform constraint at scale.
- The operating partner is advising across six portfolio companies simultaneously. Applying consistent diagnostic discipline across all six without a systematic framework means each company gets a different version of the operating partner's intuition rather than a repeatable verifiable methodology.
- A portco CEO is describing their performance problem as a market problem. Three conversations in you are realizing it is an organizational constraint that has been producing market-shaped symptoms for years.
- The board presentation requires documented evidence that the operating partner's recommendations are grounded in a systematic diagnostic methodology — not just operating experience. The methodology exists. The credential does not.
- A co-investor or LP is asking pointed questions about the operational improvement framework being applied across the portfolio. The answer is experience-based. It is not credentialed. There is a difference that sophisticated institutional investors feel immediately.
- The value creation plan has been revised twice. The initiatives have been reprioritized. The constraint has not been named. The next revision will produce the same result as the previous two.
- The exit timeline is approaching and the EBITDA improvement that was supposed to have happened is instead the story being told to prospective buyers about what the next owner will unlock — which is a very different conversation from the one that was planned at close.
Why Value Creation Plans Miss Their Targets — The Diagnostic Step That Almost Always Gets Skipped
Private equity has moved decisively from financial engineering to operational improvement as the primary returns driver. That shift is well understood across the industry. What is less well understood is the specific reason operational improvement plans miss their targets at the rate they do.
It is not execution failure. Most portco management teams execute reasonably well against a plan they understand and believe in. It is diagnostic failure — the plan was designed around the symptoms visible in the financial statements and the operational observations made during diligence, rather than around the governing constraint that is producing those symptoms.
The governing constraint is the one structural factor in the portfolio company — in its market position, its operational design, its working capital deployment, its organizational dynamics, its strategic priorities, its leadership cadence, or the credibility of the people driving the change — that limits every other improvement simultaneously. Until it is named, every initiative in the value creation plan is improving performance around the constraint rather than through it.
The result is incremental improvement against a plan that projected structural improvement. That gap is where hold periods extend, LP relationships strain, and exit multiples compress. It is also where the operating partner spends the most time — managing the symptoms of a constraint that has never been named precisely enough to remove.
The Seven Constraint Categories — Applied at the Portfolio Company Level
Every governing constraint in every portfolio company lives in one of seven categories. The category determines the intervention. The intervention determines the EBITDA outcome. Identifying the wrong category produces the wrong intervention — which is precisely what most value creation plans do when they are written before the diagnostic is complete.
What Happens When the Operating Partner Walks into the Board Meeting with a Written Constraint Diagnosis
The $89 Business Constraint Diagnostic is an 81-question diagnostic the portfolio company CEO or leadership team completes online in approximately 15 minutes. Within 72 hours they receive a written report naming the specific governing constraint across all seven categories.
Here is what changes when that report is on the table at the first board meeting.
You are sitting across from the portco CEO and the board. The written constraint report is in front of every person in the room. You open the conversation with: "Here is the constraint governing your results. It lives in the operational category. Here is specifically what it is. Here is why the initiatives in your current plan have been producing incremental improvement rather than the structural shift the investment thesis requires. And here is the specific intervention that changes that."
That is not an operating partner's opinion. That is a diagnosis. Backed by a systematic, credentialed methodology that the CEO, the co-investors, and the LP observers in that room can verify in real time through the SAI Credential Registry.
The CEO who receives that presentation is no longer receiving external advice about their business. They are receiving a written diagnosis of the specific factor that has been limiting their results — often for years before the acquisition. That is received differently than any recommendation that preceded it. The board that sees that presentation is no longer evaluating the operating partner's experience level. They are evaluating a documented diagnostic finding. Those two conversations produce very different outcomes for the hold period that follows.
And when the LP asks at the next meeting what systematic diagnostic framework is being applied across the portfolio — the answer is no longer a description of operating experience. It is a credential. Verifiable. Named. Backed by 20 published volumes and 50 years of real operating decisions. That is a different firm-level narrative than almost any competitor in your market currently holds.
Which SAI Credential Is Right for Your Role
SAI credentials are standalone programs — each one selected based on how constraint Diagnostic will be applied in your specific operating role and portfolio context. No credential is a prerequisite for another. Choose based on where you operate and what you need to deliver.
FDC — Foundational Diagnostic Credential — $697
Best for: Portfolio company CEOs and leadership teams who want to build permanent internal diagnostic capability that outlasts the hold period and survives the exit.
Application: Teaches the portco leadership team to identify and diagnose governing constraints independently — permanently, without ongoing operating partner support — making the capability a transferable asset that increases company value at exit. Most useful as a portco leadership team deployment during the hold period.
CAS — Certified Axiom Strategist — $1,997
Best for: Operating consultants, value creation advisors, and operating specialists who work within individual portfolio companies and want a verifiable systematic diagnostic methodology for every portco engagement.
Application: Deploy constraint diagnosis as the opening step of every new portco engagement — compress discovery, establish diagnostic authority at the company level, document outcomes in a format that supports operating partner reporting. Most selected by PE Operating Consultants and Value Creation Specialists.
CAE — Certified Axiom Executive — $4,997
Best for: PE operating partners and senior operating advisors who advise at the board level across multiple portfolio companies simultaneously and need a credential that holds authority in LP and governance conversations.
Application: Enterprise-level constraint diagnosis across complex multi-company structures — board-ready diagnostic presentation frameworks that move LP conversations from experience-based to methodology-based, and priority placement in the SAI Practitioner Referral Network. Most selected by PE Operating Partners. Application required — reviewed personally by Lawrence M. Schneider.
Compare All Programs Side by Side →
“The constraint that is limiting your portfolio company's performance right now was present when the deal closed. It was present when the value creation plan was written. It is still present now. The only thing that changes that is naming it — specifically, in writing, before the next initiative is designed around it.” — Lawrence M. Schneider, Founder and CEO, Schneider Axiom Institute — Founder of U.S. Lock Corporation, now owned by Home Depot
Lawrence M. Schneider spent more than 50 years making operating decisions in real companies — including exits, recessions, and the specific organizational, financial, and leadership constraints that PE-backed companies face under hold period pressure. He did not build the SAI methodology by studying portfolio companies. He built it by running businesses through the same pressures your portfolio companies are facing right now. The CAE certification carries that specific operating credibility into every board presentation, every portco engagement, and every LP conversation a certified operating partner takes. When an institutional investor asks what systematic diagnostic framework is being applied across the portfolio — the CAE is the verifiable, credentialed, documented answer.
Seven Documented Outcomes — All Seven Constraint Categories Represented
The outcomes below document what changes when a portfolio company's governing constraint is identified and removed during the hold period. Each one names the constraint category, the specific intervention that followed the diagnosis, and the EBITDA or operational result that was produced. These are the kinds of outcomes that belong in LP reports — not as general improvement narratives but as specific, categorized, intervention-linked results.
Operational Category
Named a production scheduling bottleneck at a manufacturing portco that had been limiting throughput for three years — identified during post-acquisition diagnostic rather than during diligence. Restructured the scheduling process without capital investment. Result: On-time delivery improved from 74% to 96% within 30 days. EBITDA improvement accelerated by one full quarter against the value creation plan timeline.
Financial Category
Identified a working capital allocation constraint directing cash toward slow-moving inventory while fast-moving SKUs were consistently undersupplied — presenting in the statements as a margin problem requiring price increases. Result: Gross margin recovered four points within one quarter without a price increase. The constraint had been misidentified as a pricing problem for two years prior to acquisition.
Organizational Category
Named a structural silo at a distribution portco between the sales team and operations — every customer commitment was being made without operations visibility, producing chronic delivery failures the 100-day plan had attributed to capacity. Result: Customer satisfaction improved 31 points within 90 days. The capacity investment that had been planned and budgeted was cancelled — the constraint was organizational, not operational.
Strategic Category
Identified a strategic constraint at a professional services portco — the leadership team was pursuing three growth initiatives simultaneously under hold period pressure, none of which had sufficient organizational attention to gain traction before the next initiative was added. Result: First initiative completed and producing revenue within 60 days of constraint removal. EBITDA trajectory shifted materially against the value creation plan within one quarter.
Market Category
Identified a market positioning constraint at a manufacturing portco — the company was competing on price in a segment where its actual product differentiation commanded a significant premium. The constraint had been misidentified as a sales execution problem and addressed with sales training for two consecutive years. Result: Average deal size increased 40% within two quarters of repositioning. Exit multiple improved materially as revenue quality and predictability both improved.
Leadership Category
Named a Leadership constraint at a services portco — the CEO's decision-making bottleneck was creating delays that cascaded through every operational initiative in the value creation plan. Every board directive required three follow-up conversations before it moved. Result: After the constraint was named and addressed directly, initiative implementation velocity doubled. Two previously stalled value creation initiatives advanced to completion within 60 days.
Credibility Category
Identified a Credibility constraint between a newly appointed operating partner and the incumbent portco management team — the operating partner's recommendations were technically sound but being filtered through institutional resistance rather than implemented at the speed the hold period required. Result: After the constraint was named and addressed directly with both parties, implementation velocity increased significantly. The engagement produced its projected EBITDA outcomes three months ahead of the value creation plan timeline.
Portfolio-Wide Deployment — The Firm-Level Conversation This Makes Possible
For PE firms deploying the $89 Diagnostic across multiple portfolio companies simultaneously, SAI offers volume pricing and a firm-level coordination structure that makes portfolio-wide diagnostic deployment straightforward to initiate and manage.
The deployment model works in three stages. The operating partner or firm-level decision-maker completes the $89 Diagnostic individually first. If the report identifies a clear, actionable constraint and you are satisfied with the diagnostic quality — the portfolio-wide deployment proceeds at the applicable group rate. Each portfolio company CEO or designated leadership team member completes the Diagnostic individually. Within 72 hours each company has a written constraint report. The operating partner receives an aggregated portfolio-level summary identifying the distribution of constraint categories across the portfolio — which becomes the diagnostic foundation for every value creation conversation, every board presentation, and every LP update that follows.
An operating partner who walks into an LP annual meeting and says "we deployed a written constraint diagnostic across every portfolio company before writing the value creation plan" is making a statement about operational discipline that almost no competitor firm in the market can match. It is not a narrative about experience or intuition. It is a documented, systematic, repeatable process — applied consistently across the portfolio, producing written findings that support every governance and reporting conversation the firm has.
That is a firm-level differentiator. At $79 per Diagnostic for groups of 10 to 49, a ten-company portfolio deployment costs less than one hour of operating partner advisory time per company.
Contact SAI About Portfolio-Wide Deployment →
A Note on the Operational Frameworks Already in Place at Your Portfolio Companies
Many portfolio companies arrive in the portfolio already running EOS, Lean, Six Sigma, or similar operational frameworks installed by previous management or recommended during the acquisition process. The SAI diagnostic is not a replacement for any of them. It is the step that identifies which specific constraint is preventing those frameworks from producing the operational improvement they were designed to produce. A portfolio company running a Lean program with an unidentified organizational constraint will continue to improve the wrong processes until the constraint is named. The SAI Diagnostic names it — in writing, in 72 hours — and every operational framework already in place starts working the way the value creation plan assumed it would.
The Axiom Leaders Circle
The governing constraint limiting your portfolio company's performance has almost certainly already been resolved by someone in The Axiom Leaders Circle — often by an operating partner or practitioner in a completely different portfolio context who recognized the same structural pattern.
A PE operating partner whose portfolio company is navigating an Organizational constraint — the structural silo that makes every cross-functional value creation initiative hit resistance at the same organizational level — will find the most precise input from a practitioner who has already restructured that specific authority pattern at a different portfolio company. The constraint class is the same even when the industry, the deal size, and the investment thesis are completely different.
Every Circle member has completed the same 81-question Business Constraint Diagnostic. That shared diagnostic language is what makes the Circle uniquely valuable for operating partners — because constraint patterns that present as market problems at one portfolio company present as leadership problems at another and financial problems at a third. The underlying structural cause is frequently the same category. The diagnostic language names it across all three.
Membership is free. The only prerequisite is the $89 diagnostic you may already be considering.
Join The Axiom Leaders Circle — It's Free →
Who This Is Not For
SAI programs are not the right fit for every PE context and we are direct about that.
This is not the right fit if your firm's value creation thesis is primarily financial — leverage optimization, multiple expansion through financial engineering, or cost reduction through headcount. The SAI methodology addresses operational, organizational, strategic, leadership, market, financial allocation, and credibility constraints in operating companies. It is not a financial restructuring tool and is not positioned as one.
It is not the right fit if your portfolio company management teams are not willing to engage honestly with a written diagnostic process. The $89 Diagnostic requires 81 questions answered with genuine self-assessment. A portco CEO who answers the questionnaire defensively rather than honestly will not produce a report that reflects the actual governing constraint — and the value creation plan built on that report will have the same diagnostic problem as the one it replaced.
It is not the right fit if the operating partner or firm does not intend to adjust the value creation plan based on what the diagnostic finds. The Diagnostic identifies the constraint and provides a resolution path. That finding should change how the plan is designed. If the plan will not be adjusted based on the diagnostic output — the diagnostic is not being used as intended.
If your firm is committed to operational value creation, your operating partners want a verifiable systematic diagnostic methodology that holds authority in board and LP conversations, and your management teams are willing to engage with a written diagnostic process — this was built for your portfolio.
RECOMMENDED READING
These volumes were written for the structural patterns that most commonly govern the EBITDA gaps PE operating partners are retained to close — the leadership dependency that buyers discount most aggressively, the strategic diffusion that produces initiative failure under hold period pressure, and the exit architecture gap that determines whether the transaction reflects structural potential or constrained output.
VOLUME 13 — Exit Strategy
Build a Business Worth Buying — and Get the Price You Deserve
The governing constraint suppressing a portfolio company's EBITDA is identifiable before the value creation plan is written. Volume 13 gives operating partners and their portfolio companies the framework to identify and remove the structural constraint during the hold period — so the exit multiple reflects the company's structural potential rather than the constrained output that was present at close.
$9.99
VOLUME 12 — Too Smart to Scale
Why High-Achieving Founders Build the Very Bottlenecks That Trap Them
The Leadership constraint that makes a founder-led portfolio company appear untransferable to buyers — and that produces the key-person discount that compresses exit multiples most predictably — is the single most common constraint in PE-backed founder-led businesses. Volume 12 gives operating partners the framework to name it and address it systematically during the hold period.
$9.99
VOLUME 9 — Burn the Playbook
Stop Following Yesterday's Rules and Start Building Tomorrow's Business
The Strategic constraint that allocates a portfolio company's organizational attention across too many simultaneous value creation initiatives ensures that none of them reaches the traction point the hold period timeline requires. Volume 9 names the structural priority misalignment that produces initiative failure under hold period pressure — and gives the operating team the framework to concentrate correctly.
$9.99
If You Are Still Deciding
“I am not sure the $89 Diagnostic will identify anything our diligence process did not already find.”
Standard diligence identifies financial constraints visible in the statements and operational observations accessible during site visits. The $89 Diagnostic identifies the governing constraint across all seven categories — including organizational, strategic, leadership, and credibility constraints that are structurally invisible during a standard diligence process. The constraints that extend hold periods are almost never the ones diligence found. They are the ones diligence did not look for. The Diagnostic costs $89. The cost of a value creation plan aimed at the wrong constraint is measured in missed EBITDA quarters and compressed exit multiples.
“I am not sure whether CAE or CAS is the right credential for our operating partners.”
If your operating partners are advising at the board level across multiple portfolio companies simultaneously — CAE. If your operating consultants and value creation specialists are working at the business unit or single-company level — CAS. Coffee with Larry is a free 30-minute call. Lawrence M. Schneider reviews every CAE application personally and will tell you directly which credential fits the specific operating role and the portfolio context your firm operates in.
“I am not sure the CAE credential will change anything meaningful in our LP relationships.”
The CAE changes one specific and significant thing in an LP conversation — it moves the operating improvement recommendation from an experienced opinion to a credentialed, documented, systematic methodology. Experienced opinions are questioned by institutional investors who have seen experienced opinions miss before. A credentialed methodology with a verifiable registry entry and 20 published volumes behind it is evaluated differently. That difference is most visible precisely in the moments when the value creation plan is behind schedule and the LP wants to understand what systematic process is being applied to get it back on track.
“I want to deploy this across one portfolio company before committing to a portfolio-wide program.”
That is exactly the right approach and the one we recommend. Start with one company. Complete the $89 Diagnostic at the individual level first. If within 72 hours of report delivery the report does not identify a clear, actionable constraint, email us at info@schneideraxiom.org to request a full refund. After 72 hours refunds are no longer available. If the report delivers what it describes — deploy across the portfolio with full confidence in what the process produces.
Pricing and Guarantee
Every portfolio-wide deployment begins the same way regardless of portfolio size — the operating partner or firm-level decision-maker completes the $89 Business Constraint Diagnostic individually first.
Individual Diagnostic — $89
Groups of 10 to 49 — $79 per person
Groups of 50 or more — $69 per person
If within 72 hours of report delivery the report does not identify a clear, actionable constraint, email us at info@schneideraxiom.org to request a full refund. After 72 hours refunds are no longer available. Group deployment pricing is non-refundable once the engagement leader has approved and the deployment has been initiated.
All credential program enrollments — FDC, CAS, and CAE — are non-refundable. Please review the program details carefully and schedule a free Coffee with Larry call before enrolling if you have any questions about whether a program is the right fit for your situation.
For complete pricing details and group deployment structure →
How to Get Started
No prerequisite is required for the CAE or CAS. For portfolio-wide deployments contact SAI before purchasing to set up the firm-level coordination call with Lawrence M. Schneider.
Start with the $89 Diagnostic — Deploy at One Portfolio Company First →
Apply for CAE — $4,997. Application Required. →
Enroll in CAS — $1,997. No Prerequisite. Referral Network Eligible. →
Schedule Coffee with Larry — Free, 15 Minutes, No Agenda. →
Inquire About Portfolio-Wide Deployment — Contact SAI Directly →
Frequently Asked Questions
Can the $89 Diagnostic be deployed across an entire portfolio simultaneously?
Yes. SAI supports portfolio-wide deployments for PE firms deploying the Diagnostic across multiple portfolio companies at the same time. Contact SAI before initiating any portfolio-wide deployment to set up the firm-level coordination call. The operating partner or firm-level decision-maker completes the $89 Diagnostic individually first. If satisfied the portfolio-wide deployment proceeds at $79 per person for groups of 10 to 49, or $69 per person for groups of 50 or more.
What does the operating partner receive from a portfolio-wide deployment?
In addition to the individual written report each portfolio company participant receives, the operating partner receives an aggregated portfolio-level summary. This summary identifies the distribution of constraint categories across the entire portfolio, the most common constraint categories across all deployed companies, and recommended value creation priorities based on what the diagnostic actually found at each company. This document is designed specifically to support LP reporting and board-level value creation presentations — it gives every hold period conversation a diagnostic foundation rather than an initiative-tracking foundation.
How does the SAI methodology interact with operational playbooks and frameworks already in place at portfolio companies?
Portfolio companies running EOS, Lean, Six Sigma, or proprietary operational playbooks benefit from the SAI diagnostic rather than competing with it. The diagnostic identifies the governing constraint that is preventing the existing framework from producing the results the value creation plan projected. Once the constraint is named and the intervention is made, the operational framework that was already in place starts producing the improvement it was designed to produce — often without any modification to the framework itself.
How is the CAE different from the CAS for PE operating partners specifically?
The CAS is designed for practitioners working at the business unit or single-company level — operating consultants and value creation specialists embedded in one portfolio company at a time. The CAE is designed for operating partners advising at the board level across multiple portfolio companies simultaneously. The CAE includes enterprise-level diagnostic frameworks for multi-company structures, board-ready presentation frameworks that translate constraint findings into LP governance language, and priority placement in the SAI Practitioner Referral Network. The practical test is straightforward — if you are regularly in board meetings across multiple companies and your credibility in those meetings depends on the authority of your diagnostic methodology, the CAE is the right credential.
Why is an application required for the CAE?
The CAE is designed for senior operating advisors working at the enterprise and portfolio governance level. The application process ensures alignment between the candidate's actual operating experience and the enterprise-level content the CAE contains. Every application is reviewed personally by Lawrence M. Schneider. The review is not a barrier — it is a quality signal that the CAE means something. Lawrence M. Schneider will tell you directly whether the CAE or the CAS is the better fit for your specific operating role and portfolio context.
What is the guarantee on the $89 Diagnostic?
If within 72 hours of report delivery the report does not identify a clear, actionable constraint, email us at info@schneideraxiom.org to request a full refund. After 72 hours refunds are no longer available. All credential program enrollments — FDC, CAS, and CAE — are non-refundable. Please review the program details carefully and schedule a free Coffee with Larry call before enrolling if you have questions about whether a program is the right fit.
The governing constraint limiting your portfolio company's performance was present when the deal closed. The $89 Diagnostic names it in 72 hours — for less than one minute of operating partner advisory fees. Name it before the next value creation initiative is designed around it.
Strengthen the individual.
Strengthen the family.
Strengthen the company.
Strengthen America.